Sinéad M. Ryan1,2, Hetal B. Patel3, Kristin N. Kornerup3, Anita Umerska4, Lidia Tajber4, Mauro Perretti3 and David J. Brayden1*
1*School of Veterinary Medicine and Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland, 2School of Food Science and Environmental Health, Dublin Institute of Technology, Cathal Brugha Street, Dublin 1, Ireland, 3William Harvey Research Institute, Barts and The London School of Medicine, Queen Mary; University of London, UK and 4School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin 2, Ireland
Salmon calcitonin (sCT) is a potential therapeutic for targeting the orphan nuclear receptor NR4A biomarker in order to treat human inflammatory joint disease . While the analgesic actions of sCT are well described, it is typically not used for that effect. Its ability to reduce expression of the possible inflammatory biomarker family (NR4A) is a novel finding and could permit the manufacture of new analgesic formulations based on polymers for intraarticular (IA) delivery for arthritis. sCT was formulated into a nanocomplex of hyaluronic acid (HA) and chitosan. A single intra-articular (IA) injection of sCT nanoparticles (sCT-NPs) was administered into the knee of a novel murine model of inflammatory arthritis K/BxN. The treatment reduced joint swelling; the clinical score was on a par with the positive control, dexamethasone, and joint histology was largely restored.